Neurology · NarcolepsyTrial Updateclinicalmid-term

Cleminorexton Study for Narcolepsy Type 1 and Type 2 Initiated by Centessa Pharmaceuticals

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Centessa Pharmaceuticals2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/14/2026, 12:30:37 PM

Assessment confidence: 69% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial of cleminorexton by Centessa Pharmaceuticals could significantly impact the treatment landscape for narcolepsy, addressing unmet medical needs. Success in this trial may enhance Centessa's competitive positioning in neurology and expand their therapeutic portfolio. Regulatory context from FDA (FDA TA — ANDA219413) supports the near-term read. Assessment grounded in 22 ranked evidence items (12 high-relevance).

Strategic Assessment

If successful, cleminorexton could enhance Centessa's portfolio in neurology and address unmet needs in narcolepsy management. The strongest clinical anchor is A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence (ClinicalTrials.gov), entity match (centessa pharmaceuticals). In Neurology · Narcolepsy, 6 regulatory and 3 competitive items passed relevance filtering for Centessa Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders (Lilly) — entity match (centessa pharmaceuticals). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This trial positions Centessa Pharmaceuticals in the competitive landscape for narcolepsy treatments, potentially offering a new therapeutic option targeting orexin pathways.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — ANDA219413 (FDA). Regulatory pathway relevance (nda). The trial's outcome will influence future regulatory submissions and approvals, particularly if cleminorexton demonstrates safety and efficacy in treating narcolepsy.

Key Risks

Elevated medium regulatory exposure for Centessa Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If cleminorexton proves effective, it could capture market share in the narcolepsy treatment segment, potentially leading to increased revenue for Centessa Pharmaceuticals.
Upside for Centessa Pharmaceuticals may improve if A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB) (ClinicalTrials.gov) delivers favorable follow-through.
If successful, cleminorexton could enhance Centessa's portfolio in neurology and address unmet needs in narcolepsy management.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for safety and efficacy data, as well as any announcements regarding further development stages.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — ANDA219413
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — LAROTRECTINIB (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VYEPTI (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA TA — VERICIGUAT (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VYEPTI (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA TA — VERICIGUAT (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
ClinicalTrials.govhigh relevance
Entity match (centessa pharmaceuticals)
FDA document
View source
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparative Evaluation of Sustained meChanical AsPiration Thrombectomy and no Thrombus Modification for Pre-stent Thrombus bUrden Reduction in Patients With Acute Myocardial Infarction Study: the CAPT
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Lillyhigh relevance
Entity match (centessa pharmaceuticals)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation
Humanexa Signalsmedium relevance
Moderate corpus alignment

Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Centessa Pharmaceuticals

Commercial impact

medium

If cleminorexton proves effective, it could capture market share in the narcolepsy treatment segment, potentially leading to increased revenue for Centessa Pharmaceuticals.

Regulatory impact

medium

The trial's outcome will influence future regulatory submissions and approvals, particularly if cleminorexton demonstrates safety and efficacy in treating narcolepsy.

What to watch

Monitor trial results for safety and efficacy data, as well as any announcements regarding further development stages.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.